Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University: Squamous Cell Carcinoma of Head and Neck trials

The registry lists 21 Squamous Cell Carcinoma of Head and Neck studies with Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University as lead sponsor. 10 are open to participants now and 0 have results posted.

Phase 2 16Phase 3 5No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Discovery and Validation of Biomarkers for Periodontitis, Dental Caries and Oral Squamous Cell CarcinomaNot yet recruitingNCT07745803
• Postoperative Radiotherapy With Nimotuzumab ± Benmelstobart in Intermediate-Risk Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT07535567Phase 2/3
• Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck Squamous Cell CarcinomaRecruitingNCT07445048Phase 3
• De-Escalation Surgery After Immunotherapy in Locally Advanced Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT07320690Phase 3
• Iparomlimab and Tuvonralimab in HNSCCRecruitingNCT07090317Phase 2
• Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCCRecruitingNCT07088211Phase 2
• Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negative, Anti-PD-1-resistant R/M HNSCCRecruitingNCT06935188Phase 2
• Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT)Not yet recruitingNCT06647563Phase 3
• Tirilizumab with Albumin-bound Paclitaxel and Cisplatin for Locally Advanced Resectable Oral Squamous Cell CarcinomaRecruitingNCT06470217Phase 2
• Elective vs Therapeutic Neck Dissection in Treatment of Patients With Clinical T1/2N1M0 Oral Squamous Cell CarcinomaNot yet recruitingNCT05806073Not applicable
• Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCCActive, not recruitingNCT06081673Phase 2
• Cetuximab Plus Dalpicilib in Patients With HPV Negative, PD-1 Resistant R/M HNSCCCompletedNCT05721443Phase 2
• Camrelizumab Plus Docetaxel and Cisplatin in Recurrent or Metastatic Oral Squamous Cell Carcinoma PatientsStatus unknownNCT05611463Phase 2
• Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCCCompletedNCT05156970Phase 2
• A Multicenter Phase II Trial of Post-operative Concurrent Chemoradiotherapy Using Weekly Cisplatin With Tislelizumab for Patients With High-risk Head and Neck Squamous Cell Carcinoma：The POTENTIAL StudyStatus unknownNCT04814069Phase 2
• Concurrent Immunotherapy With Postoperative Radiotherapy in Intermediate/High Risk HNSCC Patients Unfit for Cisplatin: The IMPORT Study (IMPORT)Status unknownNCT04523883Phase 2
• Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell CarcinomaStatus unknownNCT04440917Phase 2
• A Study of Apatinib and Tegafur Gimeracil Oteracil in Locally Advanced Squamous Cell Carcinoma of the Head and NeckCompletedNCT03267121Phase 2
• A Study of Apatinib Plus Tegafur Gimeracil Oteracil in Recurrent/Metastatic Head and Neck CancersStatus unknownNCT03096184Phase 2
• Postoperative CCRT With Docetaxel vs Cisplatin in High Risk Oral Cavity CancerCompletedNCT02923258Phase 2/3
• Postoperative Concurrent Chemoradiotherapy With Docetaxel for High-Risk Squamous Cell Carcinoma of Head and NeckCompletedNCT02776137Phase 2